Analgesic Efficacy of Maxigesic in Breast Cancer Surgery
Recruiting · NCT06174363 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
0.9% saline solutionMaxigesic
What this trial is about
The present study aims to find a perioperative analgesic method that provides sufficient analgesia while reducing immune compromise in cancer surgery. This study is to investigate the analgesic effect and safety of Maxigesic inj. (a combination of acetaminophen 1000 mg and ibuprofen 300 mg), which is added to opioid-based IV-PCA in patients undergoing breast cancer surgery.
Who can take part
Age range
20 Years to 70 Years
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patient aged 20 to 70 years with ASA classification 1 to 3 undergoing breast cancer surgery (cancer resection or reconstruction)
Exclusion criteria
- ASA classification 4/ allergy to acetaminophen, NSAIDs, opioid/ severe liver or renal dysfunction/ pregnancy
Where it is running
1 location listed.
- Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine - Seoul, South Korea